Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.
about
Pharmacokinetics and pharmacodynamics in antibiotic dose optimization.Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance.A review of the pharmacokinetics and pharmacodynamics of aztreonam.What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.In Vitro and In Vivo Activities of OP0595, a New Diazabicyclooctane, against CTX-M-15-Positive Escherichia coli and KPC-Positive Klebsiella pneumoniae.Prediction of in vivo and in vitro infection model results using a semimechanistic model of avibactam and aztreonam combination against multidrug resistant organisms.Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model.The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.In vitro and in vivo activities of the diazabicyclooctane OP0595 against AmpC-derepressed Pseudomonas aeruginosa.In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms.Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.Avibactam Pharmacokinetic/Pharmacodynamic Targets.β-lactam/β-lactamase inhibitor combinations: an update
P2860
Q38664871-DD234589-4AA1-48BD-954A-C711397BD3C4Q38672016-C199A71C-F2E2-4D89-8FDA-0472D3A9C83EQ38873850-F9948033-DC2A-4AF0-9F23-490743C551A6Q39120027-676221B8-D7F7-4F46-B9C5-2E7541449BFBQ39940279-8CBF1636-17FD-4D17-A8CD-C45A32C415CAQ40350783-2580D6A8-77A9-422C-8088-A0AD6BA0303FQ40375783-9F4518CE-E382-4ED6-8D08-602D3E752ED2Q40389902-A32819DD-31DC-4EEC-A14F-7138F720222DQ40401367-6F14DAF0-A64B-45BE-9BB4-F2A2FAAE271AQ40702364-E5D40139-02B8-4803-B49C-C672164EE1DEQ47677671-474673A8-67FE-4A0D-B774-B6F8CBC81E01Q48223697-346A631E-BDE8-49A8-AE68-D0484E173854Q52611981-8342FCFE-9FA8-4C16-996F-6FED27445D52Q57133147-4DA91CF0-A9BD-4ED2-8C3B-E5A84262CC1E
P2860
Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Pharmacokinetics/pharmacodynam ...... roach for aztreonam/avibactam.
@en
Pharmacokinetics/pharmacodynam ...... roach for aztreonam/avibactam.
@nl
type
label
Pharmacokinetics/pharmacodynam ...... roach for aztreonam/avibactam.
@en
Pharmacokinetics/pharmacodynam ...... roach for aztreonam/avibactam.
@nl
prefLabel
Pharmacokinetics/pharmacodynam ...... roach for aztreonam/avibactam.
@en
Pharmacokinetics/pharmacodynam ...... roach for aztreonam/avibactam.
@nl
P2093
P2860
P356
P1476
Pharmacokinetics/pharmacodynam ...... roach for aztreonam/avibactam.
@en
P2093
Ann E Eakin
Jennifer J Harris
John P O'Donnell
M Angela Tanudra
Renu Singh
Robert E McLaughlin
Sara Patey
P2860
P304
P356
10.1093/JAC/DKV132
P407
P577
2015-05-29T00:00:00Z